Protagonist Therapeutics Investor Presentation — March 2021

Document content

PN-943 PTG-200PN-232 PN-235rusfertide

Dinesh V. Patel , PhD

President & CEOMarch 2021COMPANY OVERVIEW

1Forward- looking Statements

2This presentation and the accompanying oral presentation contain forward- looking statements made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, includin g statements regarding our future results

of operations and financial position, business strategy, product candidates, capital resources, potential markets for our produc t candidates, enrollment in our clinical

trials, any potential impact on our business related to COVID -19, our potential receipt of milestone payments and royalties under our Collaboration Agreement with

Janssen Biotech, Inc., are forward- looking statements. In some cases, you can identify forward- looking statements by terminology such as “anticipate,” “believe,”

“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially” “predict,” “should,” “will” or the negative ofthese terms or other similar expressions.

The forward- looking statements made in this presentation involve known and unknown risks, uncertainties and other important fact ors that may cause our actual

results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking

statements. These forward- looking statements are subject to risks and uncertainties, including those discussed in Protagonist’s filings with the Securities and

Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Res ults of Operations” sections of

most recently filed periodic reports on Form 10- K and Form 10- Q and subsequent filings and in the documents incorporated by reference therein. Because forward-

looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and som e of which are beyond our control, you

should not rely on these forward- looking statements as predictions of future events. The events and circumstances reflected in our forward -looking statements may

not be achieved or occur and actual results could differ materially from those projected in the forward- looking statements. Except as required by applicable law, we do

not plan to publicly update or revise any forward- looking statements contained herein, whether as a result of any new informatio n, future events, changed

circumstances or otherwise.

This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug